IONIS PHARMACEUTICALS INC - Common Stock (IONS)

Historical Holders from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
IONS on Nasdaq
Shares outstanding
161,813,505
Price per share
$79.11
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
168,153,453
Total reported value
$11,000,942,367
% of total 13F portfolios
0.01%
Share change
-1,296,390
Value change
+$31,985,340
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
427
Price from insider filings
$84.62
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of IONIS PHARMACEUTICALS INC - Common Stock (IONS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Capital World Investors 11% +54% $1,420,918,364 +$513,889,541 17,961,299 +57% Capital World Investors 31 Dec 2025
VANGUARD GROUP INC 10% $439,981,517 16,472,539 The Vanguard Group 31 Dec 2024
T. Rowe Price Investment Management, Inc. 8.3% -17% $860,738,398 -$176,290,480 13,157,114 -17% T. Rowe Price Investment Management, Inc. 30 Sep 2025
BlackRock, Inc. 5.7% $242,166,669 9,066,517 BlackRock, Inc. 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 4.3% $221,944,703 6,879,873 Wellington Management Group LLP 30 Jun 2025
As of 30 Sep 2025, IONIS PHARMACEUTICALS INC - Common Stock (IONS) has 427 institutional shareholders filing 13F forms. They hold 168,153,453 shares. .

Top 25 institutional shareholders own 78% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
FMR LLC 15% 23,689,038 +0.19% 0.08% $1,549,736,866
VANGUARD GROUP INC 10% 16,481,730 -1.4% 0.02% $1,078,234,776
T. Rowe Price Investment Management, Inc. 8.1% 13,156,929 -18% 0.53% $860,727,000
Capital World Investors 7.9% 12,722,728 +1.5% 0.11% $832,320,866
BlackRock, Inc. 6.5% 10,447,940 -4.1% 0.01% $683,504,235
WELLINGTON MANAGEMENT GROUP LLP 4.1% 6,588,811 +3.8% 0.08% $431,040,015
Bellevue Group AG 3.9% 6,244,451 -20% 8.5% $408,511,984
STATE STREET CORP 2.7% 4,388,651 -3.1% 0.01% $287,105,548
Deep Track Capital, LP 2.4% 3,808,144 -22% 7% $249,128,780
GEODE CAPITAL MANAGEMENT, LLC 1.9% 3,066,289 +6.1% 0.01% $200,632,333
Tweedy, Browne Co LLC 1.8% 2,901,216 +0.32% 16% $189,797,551
PRICE T ROWE ASSOCIATES INC /MD/ 1.7% 2,729,685 -13% 0.02% $178,577,000
CITADEL ADVISORS LLC 1.5% 2,402,065 +61% 0.13% $157,143,093
TWO SIGMA ADVISERS, LP 1.3% 2,073,111 -22% 0.27% $135,622,922
DEERFIELD MANAGEMENT COMPANY, L.P. 1.2% 1,979,669 2% $129,509,946
TWO SIGMA INVESTMENTS, LP 0.97% 1,575,943 -12% 0.16% $103,098,191
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.94% 1,519,951 +2.2% 0.02% $99,435,194
Pictet Asset Management Holding SA 0.86% 1,393,124 +129% 0.09% $90,476,958
AMERICAN CENTURY COMPANIES INC 0.85% 1,372,225 +190% 0.05% $89,771,090
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.81% 1,315,000 -65% 0.14% $86,027,300
ROYAL BANK OF CANADA 0.76% 1,226,624 +53% 0.01% $80,244,000
MORGAN STANLEY 0.73% 1,180,316 -13% 0% $77,216,430
UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC 0.71% 1,154,166 +46% 0.02% $75,505,539
MACQUARIE GROUP LTD 0.7% 1,131,936 -21% 0.09% $74,051,000
Vestal Point Capital, LP 0.66% 1,075,000 +115% 3.2% $70,326,500

Institutional Holders of IONIS PHARMACEUTICALS INC - Common Stock (IONS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 93,644 $7,450,815 -$21,177,846 7,911.03% 11
2025 Q3 168,153,453 $11,000,942,367 +$31,985,340 6,542% 427
2025 Q2 168,850,675 $6,672,661,270 +$162,663,053 3,951% 360
2025 Q1 165,860,388 $5,004,888,304 +$131,542,106 3,017% 339
2024 Q4 160,378,503 $5,606,611,256 +$145,066,700 3,496% 348
2024 Q3 155,100,181 $6,216,457,066 +$420,090,739 4,006% 350
2024 Q2 143,207,364 $6,823,569,543 +$110,187,911 4,766% 355
2024 Q1 140,609,143 $6,095,939,090 -$80,597,812 4,335% 355
2023 Q4 358,818 $18,147,985 -$1,795,439 5,059% 6
2023 Q3 137,880,236 $6,254,243,091 +$169,761,553 4,536% 302
2023 Q2 134,530,456 $5,519,019,946 +$183,377,765 4,103% 295
2023 Q1 130,350,576 $4,656,611,449 +$29,019,556 3,574% 303
2022 Q4 129,519,273 $4,892,631,207 +$140,389,081 3,777% 326
2022 Q3 124,414,852 $5,499,320,170 -$444,927,599 4,423% 328
2022 Q2 122,655,189 $4,537,175,595 +$4,191,380 3,702% 321
2022 Q1 123,594,699 $4,576,605,983 +$93,762,962 3,703.96% 309
2021 Q4 120,736,011 $3,673,847,924 +$47,440,866 3,042.96% 313
2021 Q3 120,483,360 $4,041,377,937 -$95,095,843 3,354.02% 307
2021 Q2 122,927,880 $4,901,945,988 +$74,001,388 3,988.98% 316
2021 Q1 122,194,249 $5,495,298,156 +$76,146,892 4,495.99% 345
2020 Q4 118,009,815 $6,674,583,430 +$40,638,289 5,654% 356
2020 Q3 118,348,859 $5,615,834,883 -$83,648,035 4,744.98% 346
2020 Q2 119,819,738 $7,065,077,052 +$117,697,292 5,896% 359
2020 Q1 117,465,887 $5,554,573,364 -$141,946,284 4,728% 339
2019 Q4 120,596,438 $7,287,409,500 -$85,128,592 6,040.97% 369
2019 Q3 121,633,553 $7,283,914,763 -$289,525,281 5,990.99% 354
2019 Q2 126,475,243 $8,127,139,353 +$1,306,667,471 6,427% 379
2019 Q1 116,831,275 $9,482,852,006 +$7,275,759 8,117% 374
2018 Q4 117,086,666 $6,331,846,646 -$39,658,575 5,405.99% 309
2018 Q3 118,334,516 $6,102,880,241 +$9,203,577 5,157.99% 305
2018 Q2 118,278,757 $4,928,811,291 +$160,676,986 4,167% 294
2018 Q1 114,939,841 $5,067,050,068 +$58,052,097 4,407.96% 313
2017 Q4 113,131,179 $5,690,459,841 -$78,595,014 5,030% 300
2017 Q3 115,109,253 $5,836,224,983 +$171,227,946 5,070% 292
2017 Q2 110,878,342 $5,640,594,963 +$55,428,291 5,086.98% 281
2017 Q1 110,512,635 $4,442,926,265 +$327,554,707 4,019.96% 262
2016 Q4 107,421,418 $5,137,895,022 +$128,222,155 4,783.03% 296
2016 Q3 106,315,192 $3,893,841,306 -$66,472,307 3,664% 266
2016 Q2 108,413,527 $2,524,805,486 +$24,981,763 2,328.98% 265
2016 Q1 105,052,618 $4,254,138,314 +$23,536,743 4,050% 301
2015 Q4 103,286,638 $6,394,584,642 +$6,387,689,720 6,192.95% 328